Kabana Skin Care failed to test OTC drug ingredients and finished products, prompting a recall and halt of U.S. drug manufacturing.
What happened
FDA inspected Kabana Skin Care's drug manufacturing facility in Louisville, Colorado, from February 19 to 20, 2025. FDA found the company did not test incoming ethanol and glycerin for identity, including methanol or diethylene glycol/ethylene glycol (DEG/EG), and did not perform chemical or microbiological testing on finished drug products before release. The company later agreed to recall all drugs in U.S. distribution and permanently cease manufacturing.
What FDA found
Kabana did not test each incoming lot of ethanol and glycerin for identity, including methanol or DEG/EG contamination.
21 CFR 211.84(d)(1) and 211.84(d)(2)Kabana did not check that its component suppliers' test results were reliable at appropriate intervals.
21 CFR 211.84(d)(2)Kabana did not perform chemical or microbiological release testing on finished drug batches before distribution.
21 CFR 211.165(a)Kabana's quality control unit failed to ensure adequate oversight procedures for raw materials, production records, investigations, complaints, and recalls.
21 CFR 211.22(a) and 211.22(d)Kabana lacked an adequate stability program to support labeled expiration dates.
21 CFR 211.137 and 211.166Kabana lacked appropriate written production and process control procedures and adequate equipment cleaning and maintenance procedures.
21 CFR 211.100(a), 211.67(a), 211.67(b)
What FDA wants
FDA tells Kabana to respond in writing within 15 working days with corrections and to provide methanol or DEG/EG test results from retained high-risk component lots and a risk assessment for products within expiry within 30 calendar days. The company must also notify FDA before resuming any drug manufacturing.
Who should pay attention
- OTC drug brands that use contract manufacturers
- companies buying glycerin or ethanol for drug products
- retailers selling store-brand sunscreens or hand sanitizers
This is a summary. Read the original letter on fda.gov.